0000950170-23-028727.txt : 20230616
0000950170-23-028727.hdr.sgml : 20230616
20230616200012
ACCESSION NUMBER: 0000950170-23-028727
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230614
FILED AS OF DATE: 20230616
DATE AS OF CHANGE: 20230616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harwin Peter Evan
CENTRAL INDEX KEY: 0001663607
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36483
FILM NUMBER: 231022966
MAIL ADDRESS:
STREET 1: 2001 MARKET STREET
STREET 2: SUITE 2500
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viridian Therapeutics, Inc.\DE
CENTRAL INDEX KEY: 0001590750
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 471187261
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 203 CRESCENT STREET
STREET 2: BLDG. 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 617.272.4600
MAIL ADDRESS:
STREET 1: 203 CRESCENT STREET
STREET 2: BLDG. 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
FORMER COMPANY:
FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20170213
FORMER COMPANY:
FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20170213
FORMER COMPANY:
FORMER CONFORMED NAME: SIGNAL GENETICS, INC.
DATE OF NAME CHANGE: 20140710
4
1
ownership.xml
4
X0407
4
2023-06-14
0001590750
Viridian Therapeutics, Inc.\DE
VRDN
0001663607
Harwin Peter Evan
C/O VIRIDIAN THERAPEUTICS, INC.
221 CRESCENT STREET, SUITE 401
WALTHAM
MA
02453
true
false
false
false
false
Stock Option (Right to Buy)
27.67
2023-06-14
4
A
false
20000
0
A
2023-06-14
Common Stock
20000
20000
I
See Footnote
The option vests in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service on the Board.
Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
/s/ Lara Meisner, Attorney-in-Fact for Peter Evan Harwin
2023-06-16